COMMUNIQUÉS West-GlobeNewswire

Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition
22/04/2026
AUSTIN, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage : The biotechnology industry is experiencing a subtle yet meaningful transformation that is redefining how value is interpreted within a [...]
Microbot Medical® Welcomes Updated Occupational Protection Guidelines from Leading Medical Societies, Strengthening Commercial Position of LIBERTY®
22/04/2026
Members of the Society of Interventional Radiology (SIR) and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Represent the Largest Addressable User Market for the LIBERTY System At least [...]
Spectral AI’s DeepView® System Showcased at 2026 American Burn Association Annual Meeting
22/04/2026
DALLAS, April 22, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate [...]
CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026
22/04/2026
Ongoing Phase 2 study in metastatic colorectal cancer (mCRC) demonstrates early clinical and biomarker activity with leronlimab in combination with TAS-102 and bevacizumab, supporting CCR5 as a therapeutic target [...]
Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026
22/04/2026
CAMBRIDGE, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, [...]
Cue Biopharma Announces 1-for-30 Reverse Stock Split
22/04/2026
BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease- [...]
Autonomix Medical to Present Long-Term Pain Mitigation Data in Pancreatic Cancer at ECIO 2026
22/04/2026
THE WOODLANDS, TX, April 22, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today [...]
Accent Trial Mature Data Presented at International Conference
22/04/2026
HIGHLIGHTS Mature data from Amplia’s ACCENT trial in pancreatic cancer is being presented at the prestigious American Association of Cancer Research (AACR) annual meeting The ACCENT trial investigates the combination of [...]
Rakovina Therapeutics Presents New Preclinical Data at AACR 2026 Annual Meeting
22/04/2026
AI-Designed Dual ATR-mTOR Inhibitor Demonstrates In Vivo Efficacy; Novel LNP Formulation of Bifunctional PARP/HDAC Inhibitor kt-3283 Successfully Characterized VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE [...]
Medicines360 and Pharma Dynamics announce the launch of Avibela® in South Africa, Expanding Access to Long‑Acting Contraception and Treatment of Heavy Menstrual Bleeding
22/04/2026
SAN FRANCISCO and CAPE TOWN, South Africa, April 22, 2026 (GLOBE NEWSWIRE) -- Medicines360 and Pharma Dynamics have announced the availability of AVIBELA, South Africa’s first generic levonorgestrel 52 mg intrauterine [...]
Ojemda® approuvé dans l’Union européenne comme première thérapie ciblée pour les enfants atteints de gliome pédiatrique de bas grade (pLGG), en rechute ou réfractaire, indépendamment de l’altération de BRAF
22/04/2026
 Nouvelle option thérapeutique pour des tumeurs cérébrales pédiatriques rares et potentiellement invalidantes Moins de 10 % des nouvelles autorisations de médicaments au cours des cinq dernières années ont porté sur des [...]
Elkedonia strengthens Board of Directors with appointment of Pierre d’Epenoux as Independent Chairman
22/04/2026
Appointment strengthens Elkedonia's governance as the company continues its development and prepares for its next phases of growth Pierre d’Epenoux is former CEO of ImCheck Therapeutics, a clinical-stage biotech immuno- [...]
Elkedonia renforce son Comité stratégique avec la nomination de Pierre d'Epenoux comme Président indépendant
22/04/2026
Cette nomination renforce la gouvernance d'Elkedonia alors que la société poursuit son développement et prépare ses prochaines étapes de croissance Pierre d'Epenoux est l'ancien Président Directeur Général d'ImCheck [...]
Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children
22/04/2026
Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children Expanded approval includes children aged one year and above with stage 2 T1D to delay the onset of stage 3 Tzield is the [...]
Communiqué de presse : Tzield de Sanofi approuvé aux États-Unis pour retarder l’apparition du diabète de type 1 de stade 3 chez les jeunes enfants
22/04/2026
Tzield de Sanofi approuvé aux États-Unis pour retarder l’apparition du diabète de type 1 de stade 3 chez les jeunes enfants L'extension d'approbation inclut les enfants âgés d'un an et plus atteints de diabète de type 1 [...]
Axomove lève 4 M€ pour accélérer la commercialisation de son dispositif médical numérique de prévention et de rééducation
22/04/2026
Axomove lève 4 M€ pour accélérer la commercialisation de son dispositif médical numérique de prévention et de rééducation Ce tour d’investissement de série A est co-dirigé par le Fonds Prévention Numérique, géré par [...]
Communiqué de presse : Sanofi fait le point sur la soumission réglementaire de Sarclisa en formulation sous-cutanée aux États-Unis
22/04/2026
Sanofi fait le point sur la soumission réglementaire de Sarclisa en formulation sous-cutanée aux États-Unis Paris, le 22 avril 2026 . La Food and Drug Administration (FDA) des États-Unis a prolongé de jusqu’à trois mois [...]
Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US
22/04/2026
Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US Paris, April 22, 2026. The US Food and Drug Administration (FDA) has extended by up to three months the target action date for its [...]
Maze Therapeutics Announces $150 Million Registered Offering
22/04/2026
SOUTH SAN FRANCISCO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE) today announced the pricing of its underwritten registered offering of 5,540,000 shares of its common stock at a [...]

Pages